#Bioretec #Finland #Helsinki #RemeOs #Activa

Bioretec Ltd's Significant Developments in Stock Options and Rights Issue

Bioretec Ltd, a pioneering company in the realm of biodegradable orthopedic devices, has recently made crucial updates to its stock option programs after successfully completing a significant rights issue. On April 28, 2026, Bioretec announced that a total of 1,286,801,534 new shares were subscribed during this offering, which has been officially registered with the Finnish Patent and Registration Office. This move marks a pivotal moment for the company as it continues to expand its influence and offerings globally.

The rights issue is designed to empower existing shareholders and aligns with Bioretec’s commitment to create equitable treatment among all stakeholders, particularly for those holding stock options. In light of the completed rights issue, the Board of Directors has adjusted the subscription prices for its stock option programs to mitigate the dilutive impact on shareholders while providing an equal footing for option holders in congruence with shareholders.

The adjustments reflect a strategic vision aimed at benefiting the shareholders and ensuring the sustainability of the company's stock option framework. The revised subscription prices, which are slightly reduced from their prior values, can be seen across various option programs:

• - Program 2018-1A: Adjusted from €1.42 to €0.13
• - Program 2018-1B: Adjusted from €1.42 to €0.13
• - Program 2018-1C: Adjusted from €2.13 to €0.20
• - Program 2018-1D: Adjusted from €2.13 to €0.20
• - Program 2020-1A: Adjusted from €2.13 to €0.20
• - Program 2020-1B: Adjusted from €2.84 to €0.26
• - Program 2020-1C: Adjusted from €3.55 to €0.33
• - Program 2023-1: Adjusted from €2.35 to €0.22
• - Program 2025-1: Adjusted from €2.64 to €0.24

These changes clarify Bioretec's stance on allowing option holders to maintain a level of equity with current shareholders, showcasing the company’s strong governance commitment. The adjustable terms allow for a more dynamic response to the market conditions and shareholder actions, thereby strengthening investor confidence.

Bioretec, which is headquartered in Finland, is renowned for its innovative technologies in orthopedic care, especially through its fully biodegradable implant systems. The firm’s latest product, the RemeOs™ line, sets a standard in absorbable materials for orthopedic surgeries, gradually replaced by bone and eliminating the need for additional removal surgeries. Both FDA and CE approvals have bolstered the product's market introduction in the U.S. and Europe, respectively.

Furthermore, Bioretec's Activa line of implants also reflects their commitment to bioabsorption technologies, meeting a wide range of surgical demands effectively and compassionately for both adult and pediatric populations.

As Bioretec continues to shape the future of orthopedic treatment through innovative solutions that prioritize patient safety and ease of recovery, the adjustments made to their stock option programs highlight the company's dedication to its investors and the sustainable growth of its operations. With an ongoing focus on healing through absorption, Bioretec is poised to remain at the forefront of orthopedic care innovation.

For more information on Bioretec and its cutting-edge product offerings, please visit www.bioretec.com.